Analyst Yun Zhong of Wedbush reiterated a Buy rating on Sagimet Biosciences, Inc. Class A, retaining the price target of $28.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Yun Zhong has given his Buy rating due to a combination of factors including the promising progress of Sagimet Biosciences’ clinical programs. The company is advancing its danifanstat and TVB-3567 programs, with expectations of positive data from ongoing studies that could lead to further development in treating MASH patients with advanced fibrosis.
Additionally, the company’s financial position is strong, with sufficient cash reserves to support operations into the second half of 2027, allowing time for potential proof-of-concept data to emerge. The use of AI-based digital pathology in identifying and evaluating F4 patients further enhances the potential clinical benefits of their treatments, positioning them favorably against competitors. These elements contribute to the optimistic outlook and the reiterated outperform rating with a price target of $28.